Hydroxychloroquine No Better Than Placebo for Hand OA

Share this content:
Hydroxychloroquine No Better Than Placebo for Hand OA
Hydroxychloroquine No Better Than Placebo for Hand OA

TUESDAY, Feb. 20, 2018 (HealthDay News) -- For patients with moderate-to-severe hand pain and radiographic osteoarthritis, hydroxychloroquine is no more effective than placebo for relieving pain, according to a study published online Feb. 20 in the Annals of Internal Medicine.

Sarah R. Kingsbury, Ph.D., from the University of Leeds in the United Kingdom, and colleagues conducted a randomized trial with 12-month follow-up to examine the effectiveness of hydroxychloroquine versus placebo as an analgesic treatment of hand osteoarthritis. A total of 248 participants with symptomatic and radiographic hand osteoarthritis were randomized to hydroxychloroquine or placebo for 12 months with ongoing usual care; 210 patients completed the six-month trial.

The researchers found that mean hand pain was 5.49 and 5.66 points in the placebo and hydroxychloroquine groups, respectively, at six months, with a treatment difference of −0.16 points (95 percent confidence interval, −0.73 to 0.40 points; P = 0.57). The results were consistent with adjustment for adherence, missing data, and use of rescue medications. There were no significant differences at three, six, or 12 months for any of the secondary outcomes. On grayscale ultrasonography and power Doppler, the percentage of participants with at least one joint with synovitis was 94 and 59 percent, respectively. Treatment response was not affected by baseline structural damage or synovitis.

"Hydroxychloroquine was no more effective than placebo for pain relief in patients with moderate-to-severe hand pain and radiographic osteoarthritis," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

More U.S. Teens Are Vaping, but Use of Opioids, Alcohol Falling

More U.S. Teens Are Vaping, but Use of ...

About 37 percent of 12th graders said they had vaped within the previous 12 months

Type 2 Diabetes Risk Lower in Women With Active Migraine

Type 2 Diabetes Risk Lower in Women With ...

Prevalence of active migraine decreased linearly in the 24 years prior to diabetes diagnosis

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder

Treatment costs less than extended-release naltrexone without negative impact on outcomes

is free, fast, and customized just for you!




Already a member?

Sign In Now »